The first four months of one of these prescriptions are not the same experience as the ones that follow. The dose climbs on a fixed schedule, the side effects cluster in that window, and the people who stop mostly stop there. Every number below comes from a trial that recorded it, and the window they describe is the same window a seller’s pricing model either holds still through or does not.
What the escalation schedule actually is
STEP 4 ran a twenty-week lead-in to reach the 2.4 mg semaglutide maintenance dose, of which sixteen weeks were dose escalation and four were maintenance, and 89.0% of the 902 people who began it reached the maintenance dose [1]. SURMOUNT-1 used a twenty-week escalation period for tirzepatide across its three dose arms [2]. Twenty weeks is close to five months, which is longer than most readers expect when they buy a first month.
That is why the titration planner plots the schedule against weeks rather than listing it: the opening dose is the one a patient is on for the fewest weeks, so a seller’s price at the top of the ladder is the price that governs most of a year.
How often the gastrointestinal effects show up
In STEP 1, nausea and diarrhea were the most common adverse events with semaglutide, and 4.5% of the semaglutide group discontinued treatment because of gastrointestinal events against 0.8% on placebo [3]. STEP 4 reported gastrointestinal events in 49.1% of participants who continued semaglutide against 26.1% on placebo, with similar discontinuation rates in the two arms at 2.4% and 2.2% [1].
Hold those two figures next to each other. Roughly half the treated group reported a gastrointestinal event, and roughly one in twenty-two stopped the drug because of one. The gap between those numbers is the thing a reader planning a course of treatment needs: the common outcome is discomfort that is managed, not discontinuation.
SURMOUNT-1 reported that the most common adverse events with tirzepatide were gastrointestinal, mostly mild to moderate, and occurring primarily during dose escalation, with discontinuation for adverse events in 4.3%, 7.1% and 6.2% of the 5 mg, 10 mg and 15 mg groups against 2.6% on placebo [2]. The rate rises with the dose, which is the clearest argument in the record for escalating no faster than the schedule requires.
Where the escalation window meets the bill
A seller whose price is tied to the milligram charges more at exactly the point the drug is hardest to tolerate. That is not a coincidence or a trick; it is what a dose-priced ladder does. A reader on a rising dose at a seller like one that publishes the whole ladder can see what month four costs before month one is paid for. A reader at a seller that publishes only its entry rung finds out at the refill.
The opposite arrangement is a flat rate held at every dose, which removes the financial pressure to escalate faster or slower than the schedule says. That property is scored directly by the published rubric, and it is worth more across a year than most of the gaps between headline prices.
What none of this tells an individual
These are group rates from trial populations, and a trial population is not a general population: participants were screened, monitored and followed on a protocol. A rate of 49.1% does not mean a coin flip for any particular person, and 4.5% does not promise anything either. What the numbers support is a plan: expect the escalation window to be the hard part, expect most of the discomfort to be manageable, and have a way to reach a prescriber during it — which the seller reviews record for each service.